Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advanced-generation macrolides: tissue-directed antibiotics.

G W Amsden1

  • 1The Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326-1394, USA. guy.amsden@bassett.org

International Journal of Antimicrobial Agents
|September 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma Pharmacokinetics and Tissue Penetration of Alatrofloxacin in Morbidly Obese Individuals.

Clinical drug investigation·2016
Same author

Pharmacokinetic study of azithromycin with fluconazole and cotrimoxazole (trimethoprim-sulfamethoxazole) in healthy volunteers.

Clinical drug investigation·2013
Same author

Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers.

Clinical drug investigation·2008
Same author

Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

The Journal of antimicrobial chemotherapy·2004
Same author

Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers.

The Journal of antimicrobial chemotherapy·2002
Same author

Pneumococcal resistance: the treatment challenge.

The Annals of pharmacotherapy·2001
Same journal

Corrigendum to "Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination" [International Journal of Antimicrobial Agents, 57 (2021) 106277].

International journal of antimicrobial agents·2026
Same journal

Ecr positively regulates the activity of the PhoQ/PhoP signaling system in Klebsiella pneumoniae.

International journal of antimicrobial agents·2026
Same journal

Contribution of the Arg-33-His Replacement in the Histidine Kinase CpxA to Carbapenem and Cefiderocol Resistance in Serratia marcescens.

International journal of antimicrobial agents·2026
Same journal

Real world evaluation of HIV-1 reservoir and resistance in virologically suppressed people after 52 weeks of treatment with long-acting cabotegravir + rilpivirine.

International journal of antimicrobial agents·2026
Same journal

Molecular and Epidemiological Characteristics of Cefiderocol-Resistant Klebsiella pneumoniae: A Systematic Review and Genomic Analysis.

International journal of antimicrobial agents·2026
Same journal

Timing and regimen of antiretroviral therapy and all-cause mortality in people with HIV: A time-to-event mediation analysis via opportunistic infection.

International journal of antimicrobial agents·2026
See all related articles

Advanced-generation macrolides like azithromycin offer improved pharmacokinetic profiles, featuring high tissue concentrations and extended half-lives. This enables shorter dosing regimens for respiratory tract infections, enhancing treatment efficacy.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Erythromycin was the first clinically used macrolide antibiotic.
  • Advanced-generation macrolides include azithromycin, clarithromycin, dirithromycin, and roxithromycin.
  • These newer macrolides exhibit distinct pharmacokinetic properties compared to erythromycin.

Purpose of the Study:

  • To compare the pharmacokinetic and pharmacodynamic properties of advanced-generation macrolides, particularly azithromycin.
  • To highlight the clinical utility of azithromycin's tissue-specific concentrations.
  • To emphasize the need for new models to explain the efficacy of intracellularly concentrated antibiotics.

Main Methods:

  • Review of pharmacokinetic data for azithromycin and other advanced-generation macrolides.

Related Experiment Videos

  • Analysis of antimicrobial spectrum, including Gram-positive, atypical, anaerobic, and Gram-negative pathogens.
  • Discussion of azithromycin's concentration within polymorphonuclear leukocytes and at infection sites.

    • Main Results:

    • Advanced-generation macrolides demonstrate low serum and high tissue concentrations, with azithromycin having an extended tissue elimination half-life.
    • Azithromycin allows for a 3-day once-daily dosing regimen for respiratory tract infections, shorter than other macrolides.
    • These macrolides are concentrated in leukocytes, leading to high intracellular pathogen exposure.
    • Azithromycin and clarithromycin's metabolite show activity against community-acquired Gram-negative organisms like Haemophilus influenzae.

    Conclusions:

    • Azithromycin's unique pharmacokinetic profile, characterized by high and prolonged tissue concentrations, supports its clinical efficacy.
    • Traditional pharmacodynamic models are insufficient for explaining the effectiveness of antibiotics achieving high intracellular concentrations.
    • Future research should focus on tissue pharmacokinetic and pharmacodynamic concepts for azithromycin.